Jacobs Levy Equity Management
NBIX icon

Jacobs Levy Equity Management’s Neurocrine Biosciences NBIX Stock Holding History

Jacobs Levy Equity Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.5M Buy
520,269
+485,343
+1,390% +$64.4M 0.29% 91
2025
Q4 		$4.95M Sell
34,926
-594
-2% -$86.1K 0.02% 412
2025
Q3 		$4.99M Sell
35,520
-18,480
-34% -$2.5M 0.02% 425
2025
Q2 		$6.79M Sell
54,000
-34,915
-39% -$4M 0.03% 373
2025
Q1 		$9.83M Buy
88,915
+21,726
+32% +$2.75M 0.04% 340
2024
Q4 		$9.17M Sell
67,189
-456,979
-87% -$56.5M 0.03% 320
2024
Q3 		$60.4M Sell
524,168
-196,919
-27% -$27M 0.23% 106
2024
Q2 		$99.3M Buy
721,087
+8,289
+1% +$1.14M 0.41% 58
2024
Q1 		$98.3M Sell
712,798
-40,067
-5% -$5.47M 0.44% 53
2023
Q4 		$99.2M Buy
752,865
+60,491
+9% +$6.96M 0.5% 46
2023
Q3 		$77.9M Buy
692,374
+256,920
+59% +$27.1M 0.46% 54
2023
Q2 		$41.1M Buy
435,454
+4,118
+1% +$402K 0.24% 108
2023
Q1 		$43.7M Buy
431,336
+367,229
+573% +$38.2M 0.27% 94
2022
Q4 		$7.66M Buy
64,107
+50,540
+373% +$5.92M 0.05% 320
2022
Q3 		$1.44M Buy
+13,567
New +$1.38M 0.01% 629
2021
Q1 		– Sell
-6,308
Closed -$605K – 1086
2020
Q4 		$605K Sell
6,308
-25,173
-80% -$2.43M 0.01% 823
2020
Q3 		$3.03M Buy
31,481
+3,947
+14% +$457K 0.03% 441
2020
Q2 		$3.36M Sell
27,534
-122,910
-82% -$13.6M 0.04% 426
2020
Q1 		$13M Sell
150,444
-11,388
-7% -$1.11M 0.17% 148
2019
Q4 		$17.4M Buy
161,832
+47,903
+42% +$5.02M 0.17% 148
2019
Q3 		$10.3M Sell
113,929
-20,450
-15% -$1.91M 0.13% 206
2019
Q2 		$11.3M Buy
134,379
+50,210
+60% +$4.12M 0.16% 172
2019
Q1 		$7.42M Buy
+84,169
New +$7.04M 0.11% 258

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's NBIX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Neurocrine Biosciences (NBIX) stake by 1,390% in Q1 2026, buying an estimated $64.4M and bringing the position to 520,269 shares worth $68.5M. The position accounts for 0.29% of the portfolio, ranked #91.

Jacobs Levy Equity Management first reported a position in NBIX in Q1 2019 and has held it in 23 quarters since. The position peaked at $99.3M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Jacobs Levy Equity Management held 520,269 shares of Neurocrine Biosciences worth $68.5M as of Q1 2026.
  • Jacobs Levy Equity Management bought 485,343 Neurocrine Biosciences shares in Q1 2026, an estimated $64.4M.
  • Neurocrine Biosciences made up 0.29% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #91 holding.
  • Jacobs Levy Equity Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 23 quarters since.
  • Jacobs Levy Equity Management's Neurocrine Biosciences position peaked at $99.3M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.